Australian Pharmaceutical Industries Ltd falls 3% on trading update

Credit: Priceline

The Australian Pharmaceutical Industries Ltd (ASX: API) share price has fallen by 3% this morning after it gave the market updated guidance.

Australian Pharmaceutical Industries is the parent company of Priceline Pharmacy, Soul Pattinson Chemist and Pharmacist Advice. Its services include wholesale product delivery, retail services, marketing programs and business advisory services.

The company announced that it expected its half-year net profit after tax (NPAT) for the period ending 28 February 2018 will be approximately $26.5 million and that full-year NPAT is expected to be slightly above FY17’s.

This means that the half-year result will be down by around 9% on the prior corresponding period.

The company explained the fall in profit was due to suppressed retail conditions experienced by Priceline, which persisted until late in the Christmas trading period.

The company said the overall network sales, including dispensary, for the financial year to date were up 2% whilst the like-for-like front-of-store sales in its network had declined 2.4% for the period.

The Australian Pharmaceutical Industries CEO, Richard Vincent, said “In contrast to the strong sales we experienced during 2016, consumer pending remained subdued throughout the 2017 calendar year and we did not see that change during the Christmas period.”

“We expect to see benefits flow from the steps we have taken to address the tougher retail environment. Foremost among these are investments to enhance our total customer experience, both in-store and via our digital transformation program.”

The company said that expectations for its growth in store numbers remain unchanged. The company confirmed that its balance sheet and cash flow position are strong and that the dividend payment for the first half is expected to remain the same as the prior corresponding period.

Foolish takeaway

Australian Pharmaceutical Industries is currently trading at 14x FY17’s earnings. This could be a decent price to pick up some shares if you’ve been eyeing the business, the share price is almost the lowest it has been over the past three years since early 2015. However, I’m not a buyer at this price and I’m quite bearish on most retail stocks at the moment.

These top growth stocks are more likely to deliver the growth your portfolio needs.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Australian Pharmaceutical Industries Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.